BR112015011351A2 - composição farmacêutica de difenidol de liberação sustentada - Google Patents

composição farmacêutica de difenidol de liberação sustentada

Info

Publication number
BR112015011351A2
BR112015011351A2 BR112015011351A BR112015011351A BR112015011351A2 BR 112015011351 A2 BR112015011351 A2 BR 112015011351A2 BR 112015011351 A BR112015011351 A BR 112015011351A BR 112015011351 A BR112015011351 A BR 112015011351A BR 112015011351 A2 BR112015011351 A2 BR 112015011351A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
sustained release
diphenhydol
agents
diphenidol
Prior art date
Application number
BR112015011351A
Other languages
English (en)
Other versions
BR112015011351B1 (pt
Inventor
Reséndiz-Hernández Guadalupe
Original Assignee
Invekra S A P I De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invekra S A P I De C V filed Critical Invekra S A P I De C V
Publication of BR112015011351A2 publication Critical patent/BR112015011351A2/pt
Publication of BR112015011351B1 publication Critical patent/BR112015011351B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

resumo “composição farmacêutica de difenidol de liberação sustentada” é descrita uma composição farmacêutica de difenidol de liberação sustentada, compreendendo: (a) de 15 a 50% de cloridato de difenidol; (b) de 0,1 a 20% de um ou mais agentes de ligação; (c) de 5 a 90% de um ou mais agentes diluentes; (d) de 5 a 50% de um ou mais agentes de modificação de liberação; (e) de 0,25 a 10% de um ou mais agentes lubrificantes; e (f) 0,1 a 10% de um ou mais agentes deslizantes.
BR112015011351-6A 2013-01-16 2014-01-15 Composição farmacêutica na forma de tablete em camada única de difenidol de liberação sustentada BR112015011351B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
MXMX/A/2013/000662 2013-01-16
MX2013000662A MX356789B (es) 2013-01-16 2013-01-16 Composición de difenidol de liberación prolongada.
PCT/IB2014/000044 WO2014111799A1 (es) 2013-01-16 2014-01-15 Composición de difenidol de liberación prolongada

Publications (2)

Publication Number Publication Date
BR112015011351A2 true BR112015011351A2 (pt) 2017-07-11
BR112015011351B1 BR112015011351B1 (pt) 2021-11-23

Family

ID=51209070

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015011351-6A BR112015011351B1 (pt) 2013-01-16 2014-01-15 Composição farmacêutica na forma de tablete em camada única de difenidol de liberação sustentada

Country Status (11)

Country Link
US (1) US10188610B2 (pt)
BR (1) BR112015011351B1 (pt)
CA (1) CA2889283C (pt)
CL (1) CL2015001128A1 (pt)
CR (1) CR20150275A (pt)
DO (1) DOP2015000089A (pt)
EC (1) ECSP15030460A (pt)
GT (1) GT201500038A (pt)
MX (1) MX356789B (pt)
PE (1) PE20150888A1 (pt)
WO (1) WO2014111799A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108283625A (zh) * 2018-04-26 2018-07-17 江苏四环生物制药有限公司 一种盐酸地芬尼多片的制备方法
CN110638776A (zh) * 2019-10-25 2020-01-03 仁和堂药业有限公司 盐酸地芬尼多片的制备工艺
CN110638775A (zh) * 2019-10-25 2020-01-03 仁和堂药业有限公司 一种盐酸地芬尼多片剂及其应用
CN110934842A (zh) * 2019-11-26 2020-03-31 卓和药业集团有限公司 盐酸地芬尼多片的制备方法
CN112315925A (zh) * 2020-11-16 2021-02-05 仁和堂药业有限公司 盐酸米安色林片及其制备工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6143108A (ja) * 1984-08-03 1986-03-01 Nippon Shinyaku Co Ltd 医薬品製剤及びその製造法
WO1991006281A1 (en) * 1989-10-26 1991-05-16 Nippon Shinyaku Co., Ltd. Gastric preparation
CN1935140A (zh) 2005-09-19 2007-03-28 长沙佰川医药科技开发有限责任公司 复方盐酸地芬尼多分散片剂及其制备方法
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
EP2167048B1 (en) * 2007-05-30 2016-10-26 Wockhardt Limited A novel tablet dosage form
KR101051630B1 (ko) * 2008-10-02 2011-07-26 한국유나이티드제약 주식회사 용출률과 복용편의성이 향상된 트리메부틴 서방정
CA2753057C (en) * 2009-03-03 2018-09-11 Xenoport, Inc. Sustained release oral dosage forms of an r-baclofen prodrug

Also Published As

Publication number Publication date
WO2014111799A1 (es) 2014-07-24
CA2889283A1 (en) 2014-07-24
ECSP15030460A (es) 2017-08-31
US20150352051A1 (en) 2015-12-10
DOP2015000089A (es) 2015-05-15
MX356789B (es) 2018-06-12
BR112015011351B1 (pt) 2021-11-23
CA2889283C (en) 2020-12-29
MX2013000662A (es) 2014-07-16
CL2015001128A1 (es) 2015-10-09
US10188610B2 (en) 2019-01-29
GT201500038A (es) 2019-08-02
CR20150275A (es) 2015-07-08
PE20150888A1 (es) 2015-06-08

Similar Documents

Publication Publication Date Title
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
CU20180001A7 (es) Derivados de oxopiridina sustituidos y procesos para su preparación
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201690598A1 (ru) Аминогетероарил бензамиды в качестве ингибиторов киназы
BR112018003026A2 (pt) composições compreendendo um inibidor de pi3k e um inibidor de hdac
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
CO7111287A2 (es) Composiciones plaguicidas y procesos relacionados
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
EA201891336A1 (ru) Гетероарилгидроксипиримидиноны в качестве агонистов рецептора apj
RS54873B1 (sr) Policiklična-karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba
UA116467C2 (uk) Модулятори p2x7
EA201790785A1 (ru) Производные тетрагидроизохинолина
PH12019501178A1 (en) Thiopene derivatives as antiviral agents
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
EA201500801A1 (ru) Бензохинолоновые ингибиторы vmat2
CO2018004573A2 (es) Derivados de fenilo como agonistas del receptor 2 de cannabinoides
EA201591196A1 (ru) Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств
EA201790570A1 (ru) Модуляторы р2х7
CR20150417A (es) Compuestos de azetidiniloxifenilpirrolidina
PH12016501865A1 (en) Pyridine-2-amides useful as cb2 agonists
BR112015011351A2 (pt) composição farmacêutica de difenidol de liberação sustentada
BR112016024235A2 (pt) composições farmacêuticas compreendendo agentes antibacterianos
CR20180089A (es) Compuestos útiles para inhibir a ror-gamma-t

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/01/2014, OBSERVADAS AS CONDICOES LEGAIS.